Skip to main content
ResearchTreatments

Osimertinib Offers New Standard of Care in Stage III EGFR-Mutated NSCLC

*August 2024*

The phase 3 LAURA study (NCT03521154) showed that the drug osimertinib (Tagrisso) significantly extends survival for patients with unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutations, a patient group that had previously received a standard treatment of chemotherapy and radiation.

LAURA compared osimertinib with placebo in 216 patients. Results showed a dramatic improvement in progression-free survival (PFS) for those taking osimertinib with 39.1 months (95% CI, 31.5-not calculable) vs 5.6 months (95% CI, 3.7-7.4). The 12-month PFS rate was 74% with osimertinib vs 22% with placebo, and the 24-month PFS rates were 65% vs 13%, respectively.

While overall survival data is still being collected, early results suggest a potential benefit for osimertinib in this area. The drug was generally well-tolerated, with the most common adverse effect being lung inflammation.

Based on these findings, osimertinib could now be considered the new standard of care for this specific group of lung cancer patients.

In an interview with Targeted OncologyTM, Suresh S. Ramalingam, MD, FACP, FASCO, executive director of the Winship Cancer Institute of Emory University and first author of the LAURA study, discussed the implications of these practice-changing findings. Read more.

Share